FDA Orphan Drug Designation granted to aldesleukin for treatment of amyotrophic lateral sclerosis (ALS)

Aldesleukin is an immunomodulatory agent that has been shown to enhance regulatory T-cells function in patients with ALS, whom have decreased levels, which are associated with increased disease severity. It is currently licensed in the UK for treatment of metastatic renal cancer.